Reversal of cancer chemotherapeutic resistance by amphotericin B-A broad phase I-II pilot study

14Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.
Get full text

Abstract

In order to determine if it was possible to reverse clinically evident chemotherapeutic drug-resistance, 51 evaluable patients received chemotherapy (in doses and schedules on which they had previously demonstrated tumor progression) together with amphotericin B (AMB). AMB was given in 1-, 2-, or 4-day courses. There was 1 complete response (2%), and 5 partial responses (10%). Response rates tended to be higher in the 4-day treatment program (23%) than in the 1- or 2-day AMB treatment schedules (8%). Toxicity was that expected with chemotherapy (myelosuppression), or AMB alone (fever, chills, and reversible mild azotemia). We conclude that AMB is only infrequently able to reverse clinical drug-resistance, but that this might have palliative effects in a small number of patients in whom other standard chemotherapeutic drugs lack clinical effectiveness. © 1987.

Cite

CITATION STYLE

APA

Presant, C. A., Multhauf, P., & Metter, G. (1987). Reversal of cancer chemotherapeutic resistance by amphotericin B-A broad phase I-II pilot study. European Journal of Cancer and Clinical Oncology, 23(6), 683–687. https://doi.org/10.1016/0277-5379(87)90263-X

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free